TÁC DỤNG KHÔNG MONG MUỐN CỦA HÓA TRỊ LIỆU TRÊN TRẺ EM MẮC SARCOMA XƯƠNG TẠI BỆNH VIỆN K - CƠ SỞ TÂN TRIỀU

Abstract

While advancements in multimodal treatment have significantly improved the survival rates of children with osteosarcoma in recent years, their quality of life remains suboptimal due to the adverse effects of chemotherapy. Objective: To evaluate the adverse effects in children with osteosarcoma receiving chemotherapy. Methods: A prospective cohort study, a type of cross-sectional descriptive research was conducted on 37 children with osteosarcoma who underwent 92 cycles of chemotherapy at the Pediatric Oncology Department, National Cancer Hospital, Tan Trieu campus from July 1, 2023, to June 30, 2024. Results: Gastrointestinal adverse effects were the most common (92%), including nausea, vomiting, anorexia, constipation, and diarrhea. Hematological adverse effects were the second most common (78%), with anemia (68.5%), leukopenia (18.5%), and thrombocytopenia (2.2%). Anemia and thrombocytopenia were only observed at grade 1-2. Leukopenia was observed at both grade 1-2 and grade 3-4. Elevated liver enzymes, GOT and GPT, were observed in 26.2% and 37% of the patients, respectively. Adverse effects on the urinary system (4%) and cardiovascular system (4%) were less common. Conclusion: Gastrointestinal adverse effects were the most prevalent, followed by hematological and hepatobiliary adverse effects. These adverse effects were mostly recurrent, with low frequency and mild severity. The age of the children and the duration of chemotherapy were correlated with the chemotherapy-related adverse effects.